Verona Pharma reported a strong Q1 2025, driven by the rapid adoption of Ohtuvayre, which nearly doubled its quarterly sales. Management remains optimistic about sustained growth, supported by an ...

Verona Pharma's Ohtuvayre (ensifentrine) was approved for COPD in June 2024, introducing a novel dual mechanism of action. Ohtuvayre is priced at $2,950 per month, significantly above ICER’s ...

Verona Pharma reports $36.6 million in Ohtuvayre sales for Q4 2024, with ongoing Phase 2 trials advancing. Verona Pharma plc announced its financial results for the fourth quarter and full year of ...

Verona Pharma's Ohtuvayre, a novel COPD treatment, achieved $36 million in Q4 sales, indicating strong market interest and unmet need for new therapies. Despite aggressive pricing, Ohtuvayre's ...

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...

LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases ...

Verona Pharma is off to a promising start as it launches its first product, Ohtuvayre, a maintenance treatment for chronic obstructive pulmonary disorder (COPD). In 2024, Ohtuvayre generated sales ...

Wednesday, when the FDA approved Verona Pharma’s Ohtuvayre (ensifentrine) to treat chronic obstructive pulmonary disorder (COPD), it was a reminder of the extraordinary touch Jack had in ...

London-based Verona will market its new product under the brand name Ohtuvayre. COPD leads to an obstructed airway and excess mucus production. Smoking is a risk factor for COPD, but nonsmokers ...

Ohtuvayre is the first inhaled product with a novel mechanism of action for chronic obstructive pulmonary disease to be approved in 20 years. The FDA has approved Verona Pharma’s Ohtuvayre ...

The FDA has approved Verona Pharma’s first-in-class dual phosphodiesterase 3/4 inhibitor, Ohtuvayre (ensifentrine), for the US market. The asset is tailored towards patients with moderate to ...